Perilipin 5 links mitochondrial uncoupled respiration in brown fat to healthy white fat remodeling and systemic glucose tolerance

Violeta I. Gallardo-Montejano1, Chaofeng Yang1, Lisa Hahner1, John L. McAfee✉1,4, Joshua A. Johnson2, William L. Holland2,5, Rodrigo Fernandez-Valdivia3 & Perry E. Bickel1

Exposure of mice or humans to cold promotes significant changes in brown adipose tissue (BAT) with respect to histology, lipid content, gene expression, and mitochondrial mass and function. Herein we report that the lipid droplet coat protein Perilipin 5 (PLIN5) increases markedly in BAT during exposure of mice to cold. To understand the functional significance of cold-induced PLIN5, we created and characterized gain- and loss-of-function mouse models. Enforcing PLIN5 expression in mouse BAT mimics the effects of cold with respect to mitochondrial cristae packing and uncoupled substrate-driven respiration. PLIN5 is necessary for the maintenance of mitochondrial cristae structure and respiratory function during cold stress. We further show that promoting PLIN5 function in BAT is associated with healthy remodeling of subcutaneous white adipose tissue and improvements in systemic glucose tolerance and diet-induced hepatic steatosis. These observations will inform future strategies that seek to exploit thermogenic adipose tissue as a therapeutic target for type 2 diabetes, obesity, and nonalcoholic fatty liver disease.

1 Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 2 Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 3 Department of Pathology, Wayne State University School of Medicine Detroit, Detroit, MI, USA. 4 Present address: Pathology and Laboratory Medicine Institute, Cleveland, OH, USA. 5 Present address: Department of Nutrition and Integrative Physiology and the Diabetes and Metabolism Research Center, University of Utah, Salt Lake City, UT, USA. ✉ Email: perry.bickel@utsouthwestern.edu

https://doi.org/10.1038/s41467-021-23601-2
brown adipose tissue (BAT) is a thermogenic organ in mammals that generates heat to maintain body temperature during exposure to cold ambient temperature. In addition to brown adipocytes, “brown-like cells” called beige or brite thermogenic adipocytes are recruited in white adipose tissue (WAT) depots in response to diverse stimuli, including chronic β-agonist treatment, cold exposure, and exercise. In many thermogenic adipocytes, expression of uncoupling protein 1 (UCP1) and its activation by fatty acids drive heat production by promoting the leak of protons across the inner mitochondrial membrane, thereby uncoupling oxidative phosphorylation from the production of ATP.

Over the past 10 years, the presence of thermogenic adipose tissue in adult humans has been reported. The potential of cold-activated, UCP1-positive adipocytes in humans as a target for the treatment of metabolic diseases, such as diabetes and obesity, is the subject of recent reviews, and has emerged as an important field of study. In both humans and mice, BAT activation, for example, by exposure to cold, leads to increased uptake of both glucose and fatty acids in BAT, as well as to improved systemic glucose tolerance and insulin sensitivity.

Even though important advances have elucidated many aspects of how BAT functions, many questions remain unanswered, including how mitochondrial capacity within thermogenic adipocytes is regulated to accommodate environmental, nutritional and hormonal signals, or stresses.

Perilipin 5 (PLIN5) is a member of the Perilipin family of lipid droplet (LD) proteins that is expressed in highly oxidative tissues, such as heart, oxidative skeletal muscle, fasted liver, and adipose tissue. PLIN5 gain-of-function in COS-7 cells and OP9 preadipocytes promotes increased triacylglycerol (TAG) storage and fatty acid oxidation. Additional studies in cultured cells overexpressing PLIN5 have suggested a role for PLIN5 in the regulation of lipolysis via protein–protein interactions with adipose triglyceride lipase (ATGL) and the activator of ATGL, 1-acylglycerol-3-phosphate O-acyltransferase (ABHD5). PLIN5 has been localized to muscle mitochondria, and may play a role in promoting physical interactions between mitochondria and LDs.

In adipose tissues, PLIN5 is expressed in inguinal and epididymal WAT (iWAT and eWAT, respectively), but its highest expression among adipose depots occurs in BAT. Data from genetically engineered mouse models have suggested that PLIN5 influences systemic metabolism. Constitutive PLIN5 total body knockout mice are insulin resistant due to reduced glucose disposal in muscle and WAT. Consistent with these data, in a group of 85 nondiabetic human subjects, PLIN5 mRNA expression in subcutaneous adipose tissue negatively correlated with body mass index and positively correlated with insulin sensitivity.

In another study of human subjects, PLIN5 expression in abdominal subcutaneous adipose tissue of Finnish males positively correlated with favorable metabolic traits, including insulin sensitivity, insulin resistance, and improved systemic glucose tolerance.

We hypothesized that PLIN5 functions in BAT to augment mitochondrial respiratory and thermogenic capacity in response to increased metabolic demand, for example, during cold exposure in mice. To test this hypothesis, we generated mouse models of gain and loss of PLIN5 function, specifically in BAT. Here, we report that PLIN5 protein increases in BAT dramatically within 48 h of cold exposure and that PLIN5 augments fatty acid uptake, mitochondrial biogenesis, cristae packing, and oxidative function in BAT. In addition, we show that the effects of PLIN5 in BAT secondarily lead to smaller adipocytes in iWAT, to improved systemic glucose tolerance and insulin sensitivity, and to protection from hepatic steatosis on a high-fat diet (HFD).

Results
Perilipin 5 protein and gene expression are induced by cold exposure and β3 adrenergic agonist in brown adipose tissue. To test whether PLIN5 expression is regulated during the activation of BAT, three groups of 12-week-old male mice (C56BL/6J) housed at 23 °C were shifted to 6 °C or to 30 °C or were left at 23 °C (Fig. 1a).

To assess the induction of PLIN5 protein in BAT over a longer period of cold exposure, we assessed PLIN5 protein levels by immunoblotting at intervals from 2 h to 7 days (Fig. 1d). PLIN5 protein increased significantly by 12 h at 6 °C and reached a maximum at 48 h (Fig. 1e). In fact, PLIN5 protein in BAT at 48 h of cold exposure was 40-fold greater than PLIN5 protein after 7 days at thermoneutrality (30 °C, Fig. 1e, right panel).

In addition to exposure to cold, the pharmacological selective activation of β3 adrenergic receptors activates thermogenesis in BAT. We tested if BAT PLIN5 protein and Plin5 mRNA expression increases with the administration of a selective β3 adrenergic agonist (CL-316,243). We intraperitoneally injected 12-week-old male mice (C56BL/6J) with either Vehicle or CL-316,243 daily for 2 days or 7 days. We observed an increase in PLIN5 protein levels (Supplementary Fig. 1a) and Plin5 mRNA (Supplementary Fig. 1b) with CL-316,243 at both time points with the highest levels at 2 days of treatment, which was similar to our findings after shifting mice to housing at 6 °C.

Generation of doxycycline-inducible, brown adipocyte-specific Perilipin 5 overexpression mice (BATiPLIN5). The dramatic responsiveness of PLIN5 protein in BAT to ambient temperature or pharmacological activation of β3 adrenergic receptors suggested that its level of expression may influence critical BAT functions during cold stress. To investigate PLIN5 gain-of-function in BAT in vivo, we used the tetracycline-controlled transcriptional activation system. Inducible PLIN5 expression was conferred by a novel TRE-Plin5 allele in the C56BL/6J strain background (Fig. 1f, see “Methods” for details). The mice were bred to produce two test groups: mice carrying both the TRE-Plin5 allele and the UCP1rtTA allele, termed the “BATiPLIN5” strain, and Control mice carrying only the UCP1rtTA allele. To test PLIN5 inducibility and tissue specificity, both BATiPLIN5 mice and Control mice housed at 23 °C were fed normal chow containing doxycycline (DOX) (200 mg DOX/kg chow) for 4 weeks, and then tissues were harvested for measurement of Plin5 mRNA by quantitative real-time PCR (qPCR). BATiPLIN5 mice expressed tenfold greater Plin5 mRNA in BAT compared with Control mice, but there were no differences in Plin5 mRNA between these strains in other tissues (Fig. 1g). In addition, in mice housed at 23 °C we observed a 4.5-fold increase in Perilipin 5 protein levels in the BAT of BATiPLIN5 compared with Control mice.
Control mice (Fig. 1h). It is important to note that due to the low activity at 30 °C of the Ucp1 promoter used to express rtTA, we did not observe increased expression of PLIN5 in the BAT of mice housed at thermoneutrality (Supplementary Fig. 2).

Perilipin 5 overexpression in BAT improves glucose tolerance and insulin sensitivity at room temperature with reduction in weight only during cold exposure. Given our data that PLIN5 promotes mitochondrial function in a brown adipocyte cell line34, we asked whether PLIN5 gain-of-function in BATiPLIN5 mice would affect body weight, body composition, and/or glucose homeostasis. Both Control and BATiPLIN5 mice showed similar body weight after 25 weeks on chow diet and both gained weight on HFD with no differences between genotypes (Fig. 2a). All mice were fed diet that contained 200 mg DOX/kg diet starting at 8 weeks of age. After 8 weeks on the indicated diets, body composition and food intake were similar in both groups of mice housed 23 °C (Fig. 2b, c). Energy expenditure and multidimensional activity in mice fed chow diet and housed at 23 °C were similar in both groups (Supplementary Fig. 3). In contrast, when housed at 6 °C and fed chow diet, BATiPLIN5 mice had greater food intake compared with Control mice (Fig. 2d), but nevertheless lost more weight (Fig. 2e). Random blood glucose levels in mice housed at 23 or 30 °C overnight were not significantly different between groups, but BATiPLIN5 mice housed overnight at 6 °C showed lower random blood glucose levels than Control mice (Fig. 2f).

We next performed oral glucose tolerance tests (OGTTs) on mice fed HFD for 8 weeks and housed at 23 °C. BATiPLIN5 mice had improved glucose tolerance with lower insulin levels compared with Control mice (Fig. 2g). BATiPLIN5 mice also showed lower levels of glucose during insulin tolerance testing (Fig. 2h). We found similar results for OGTT and insulin tolerance test in mice fed Chow diet (Fig. 2i, j).

Perilipin 5 overexpression in BAT increases cold tolerance and thermogenic gene expression in brown adipose tissue. To assess whether increased expression of PLIN5 would improve the ability to maintain body temperature during cold challenge, we used implantable temperature probes to measure body temperature of BATiPLIN5 and Control mice during cold exposure at 6 °C, both acutely without access to food and chronically with food. The timeline for these experiments is outlined in Fig. 3a. For acute cold assessment, we transferred mice from 23 to 6 °C and withdrew food.
We measured body temperature every hour for 8 h. Both Control and BATiPLIN5 mice showed a decrease in body temperature with no differences between genotypes during the first 6 h. However, at 8 h the body temperature of Control mice continued to fall, while that of BATiPLIN5 mice began to increase (Fig. 3b). At 8 h, the acute cold exposure experiment ended, and ad libitum access to food was restarted. Both study groups were maintained at 6 °C, and body temperature was measured in the fed state at 9 a.m. on days 2, 4, 14, and 21. Body temperature remained higher in BATiPLIN5 mice than Control mice at each timepoint (Fig. 3c). For cold acclimation, on the morning of day 22, we withdrew food and measured body temperature every hour for 7 h. By 5 h without food, BATiPLIN5 mice began to maintain higher body temperatures than Control mice (Fig. 3d).

Perilipin 5 overexpression in BAT increases fatty acid uptake and oxidation in brown adipose tissue. Cardiac-specific overexpression of PLIN5 is associated with myocardial steatosis, thought to be due to its function on the LD as a lipolytic barrier. Similarly, PLIN5 overexpression in the liver leads to hepatic steatosis, and PLIN5 liver knockout reduces liver triglycerides. We investigated whether PLIN5 overexpression in BAT would result in increased lipid accumulation in this tissue. First, we performed conventional hematoxylin and eosin (H&E) histology of BAT harvested from BATiPLIN5 and Control mice exposed to 30, 23, and 6 °C for 16 h. We found no differences in histology at 30 °C between genotypes (Supplementary Fig. 4). However, in BATiPLIN5 mice housed at 23 °C, we observed a shift to smaller LDs when compared with Control mice (Fig. 4a), and this shift was more accentuated in mice housed at 6 °C (Supplementary Fig. 4). We found no differences in BAT weight (Fig. 4b, left panel) or BAT TAG content between BATiPLIN5 and Control mice housed at 23 °C (Fig. 4b, right panel).
However, the TAG content of the BAT from BATiPLIN5 mice housed at 6 °C overnight (Supplementary Fig. 4 and Fig.4b, right panel) was greater than that from Control mice without any differences in BAT weight between the genotypes (Fig.4b, left panel). Due to the above and previous reports that PLIN5 regulates ATGL and lipolysis28,29, and can act as a barrier to lipases38, we next investigated whether overexpression of PLIN5 in BAT affects BAT lipolysis. We measured ex vivo basal and β3 adrenergic-stimulated lipolysis in BAT explants, and found no differences between the genotypes (Fig.4c).

To assess whether BAT overexpression of PLIN5 affects circulating lipids, we measured fasting serum triglycerides and nonesterified free fatty acids (NEFA), and found a trend of lower NEFA in the BATiPLIN5 mice compared with Control mice on chow, but not HFD (Fig.4d) and a trend to lower NEFA in fed mice exposed overnight to cold (Fig. 4e). We next challenged BATiPLIN5 or Control mice with a triglyceride load by oral gavage of olive oil and measured serum triglycerides at several time points. BATiPLIN5 mice showed improved triglyceride clearance when compared with Control mice (Fig.4f). We next tested lipid clearance and tissue uptake and oxidation by injection of radiolabeled triglycerides, and found that triglyceride clearance (Fig. 4g) was increased in the BATiPLIN5 mice. Also, fatty acid uptake (Fig. 4h) and oxidation (Fig. 4i) were increased in the BAT of BATiPLIN5 mice relative to Control mice. To investigate possible mechanisms of increased fatty acid uptake in BAT, we measured gene expression of Cd36, Lpl, Angptl4, and Fatp1. Of these genes, only expression of Lpl was increased significantly in BATiPLIN5 mice relative to Controls, and only after overnight cold exposure (Fig. 4j). LPL is rate-limiting for triglyceride clearance from plasma and for tissue fatty acid uptake39, including in BAT24. We measured glucose uptake after oral gavage of radiolabeled14C-deoxyglucose in mice housed at 23 °C. We found no differences between glucose uptake into the BAT of Control and BATiPLIN5 mice or in any of the other tissues studied (Supplementary Fig. 5a).

In addition to circulating lipids and glucose, de novo lipogenesis in BAT is an important mechanism to fuel BAT thermogenesis40–42. We therefore measured expression of genes involved in de novo lipogenesis in BATiPLIN5 and Control mice housed at 23 °C and after overnight exposure to 6 °C. We found no differences between glucose uptake into the BAT of Control and BATiPLIN5 mice or in any of the other tissues studied (Supplementary Fig. 5b).
Perilipin 5 overexpression in BAT is associated with increased insulin sensitivity and decreased inflammation in iWAT. As reported above, BATiPLIN5 mice are more glucose tolerant and insulin sensitive, but we are unable to explain the improved glycemia by the mechanism of increased glucose uptake by BAT. Liver and WAT are systemic regulators of glucose metabolism and insulin action. For this reason, we next investigated whether BAT PLIN5 overexpression exerts secondary effects on iWAT or liver. Hypertrophic white adipocytes have been associated with unhealthy expansion of iWAT that may result in glucose intolerance and insulin resistance. To assess adipocyte size in BATiPLIN5 and Control mice, we performed H&E staining of iWAT. We observed a decrease in adipocyte size in the BATiPLIN5 relative to Control mice housed at 23 °C (Fig. 5a left panel, quantification right panel). These differences in adipocyte size were more marked in mice exposed to cold (Supplementary Fig. 6a). We did not observe an increase in multilocular LDs that would suggest beiging of iWAT; on the contrary, iWAT expression of beiging genes was decreased in the BATiPLIN5 mice (Fig. 5b).

Wolins’ group reported that transgenic mice with PLIN5 overexpression in skeletal muscle display increased glucose tolerance and resistance to hepatic steatosis, which they attributed to increased serum levels of FGF21. We therefore measured serum levels of FGF21 in the Control and BATiPLIN5 mice, but there were no differences in serum FGF21 between the genotypes at either temperature (Supplementary Fig. 8a).

Another characteristic of unhealthy WAT expansion is a pro-inflammatory state denoted by increased chemotactic signals.
recruitment of macrophages into WAT. We observed a significant decrease in iWAT gene expression of serum amyloid A3 protein (Saa3) and monocyte chemoattractant protein 1 (Mcp1) in the BATiPLIN5 mice (Fig. 5c). We next investigated insulin signaling by assessing basal and insulin-stimulated AKT phosphorylation in the iWAT of BATiPLIN5 mice and Control mice. We prepared lysates of iWAT freshly harvested from fasted mice at time 0 and at 5 and 15 min after intraperitoneal insulin injection, and found increased insulin-stimulated pAKT (S473) in BATiPLIN5 mice relative to Control mice (Fig. 5d, left panel), as well as an increase in Glut4 mRNA expression in the BATiPLIN5 mice (Fig. 5d, right panel). We measured ex vivo basal and β3 adrenergic-stimulated lipolysis in iWAT explants, and found that β3 agonist-stimulated lipolysis in iWAT was increased in BATiPLIN5 mice (Fig. 5e). Because Plin5 mRNA expression does not differ in gonadal WAT between BATiPLIN5 and Control mice housed at either 23 or 6°C, we did not further evaluate the phenotype of gWAT (Supplementary Fig. 8b).

Diet-induced obesity and insulin resistance are risk factors for nonalcoholic fatty liver disease. Consistent with the improvement in systemic insulin resistance and in iWAT insulin sensitivity that we observed in BATiPLIN5 mice, the livers of these mice showed significantly less steatosis than Control mice after 8 weeks of HFD, as assessed by oil red O staining (Fig. 5f), H&E staining (Supplementary Fig. 9), and biochemical TAG extraction and quantification (Fig. 5g). Protection of BATiPLIN5 mice from HFD-induced hepatic steatosis was associated with increased hepatic insulin-stimulated AKT phosphorylation at S473. (h) Pyruvate tolerance test performed on Control or BATiPLIN5 mice depicting phosphorylated AKT (S473) and total AKT. Mice were intraperitoneally injected with insulin, and liver was harvested 15 min after insulin injection (left panel) WB quantification (pAKT/AKT ratio fold change; right panel). (h) Pyruvate tolerance test performed on Control or BATiPLIN5 mice depicting phosphorylated AKT (S473) and total AKT. Mice were intraperitoneally injected with insulin, and liver was harvested 15 min after insulin injection (left panel) WB quantification (pAKT/AKT ratio fold change; right panel). (i) Pyruvate tolerance test performed on Control or BATiPLIN5 mice depicting phosphorylated AKT (S473) and total AKT. Mice were intraperitoneally injected with insulin, and liver was harvested 15 min after insulin injection (left panel) WB quantification (pAKT/AKT ratio fold change; right panel).

We observed a significant decrease in iWAT gene expression of serum amyloid A3 protein (Saa3) and monocyte chemoattractant protein 1 (Mcp1) in the BATiPLIN5 mice (Fig. 5c). We next investigated insulin signaling by assessing basal and insulin-stimulated AKT phosphorylation in the iWAT of BATiPLIN5 mice and Control mice. We prepared lysates of iWAT freshly harvested from fasted mice at time 0 and at 5 and 15 min after intraperitoneal insulin injection, and found increased insulin-stimulated pAKT (S473) in BATiPLIN5 mice relative to Control mice (Fig. 5d, left panel), as well as an increase in Glut4 mRNA expression in the BATiPLIN5 mice (Fig. 5d, right panel). We measured ex vivo basal and β3 adrenergic-stimulated lipolysis in iWAT explants, and found that β3 agonist-stimulated lipolysis in iWAT was increased in BATiPLIN5 mice (Fig. 5e). Because Plin5 mRNA expression does not differ in gonadal WAT between BATiPLIN5 and Control mice housed at either 23 or 6°C, we did not further evaluate the phenotype of gWAT (Supplementary Fig. 8b).

Diet-induced obesity and insulin resistance are risk factors for nonalcoholic fatty liver disease. Consistent with the improvement in systemic insulin resistance and in iWAT insulin sensitivity that we observed in BATiPLIN5 mice, the livers of these mice showed significantly less steatosis than Control mice after 8 weeks of HFD, as assessed by oil red O staining (Fig. 5f), H&E staining (Supplementary Fig. 9), and biochemical TAG extraction and quantification (Fig. 5g). Protection of BATiPLIN5 mice from HFD-induced hepatic steatosis was associated with increased hepatic insulin-stimulated AKT phosphorylation at
serine 473 (Fig. 5h, WB left panel, quantification right panel). Insulin suppresses hepatic gluconeogenesis through several mechanisms49. We performed pyruvate tolerance tests as an indirect method to assess whether increased hepatic insulin sensitivity was resulting in the reduced hepatic gluconeogenesis. BATiPLIN5 mice had lower levels of blood glucose after the pyruvate injection than Control mice, which suggests that hepatic gluconeogenesis is reduced in BATiPLIN5 mice (Fig. 5i).

**Perilipin 5 regulates BAT mitochondrial form and function in a UCP1-dependent manner.** Compared with white adipocytes, brown adipocytes are rich in mitochondria, have mitochondria with increased cristae packing, have multilocular LDs, and exhibit high protein expression of UCP1 (ref. 55). We previously demonstrated that siRNA-mediated PLIN5 knockdown in a brown adipose cell line was associated with reduced mitochondrial oxygen consumption rate (OCR), as well as reduced mitochondrial DNA content56. However, it is not known if PLIN5 has a direct effect on BAT mitochondria in vivo. First, we measured mitochondrial DNA as a marker of mitochondrial biogenesis. BATiPLIN5 mice had increased BAT mitochondrial DNA compared with Control mice, but only when exposed to 6 °C (Supplementary Fig. 10a). We next investigated whether PLIN5 expression affects the morphology of mitochondria by electron microscopy. Both BATiPLIN5 and Control mice were either maintained at 23 °C or exposed for 16 h to 6 °C. We measured mitochondria cristae length in individual mitochondria, and for each mitochondrion we normalized total cristae length to mitochondrial area of Control mice at 6 °C, as has been previously reported57. Remarkably, in the BATiPLIN5 mice housed at 23 °C, we observed an increase in mitochondrial cristae packing compared to Control mice, such that the degree of mitochondrial cristae packing in the BAT of BATiPLIN5 mice housed at 23 °C resembled that of Control mice exposed to 6 °C (Fig. 6a, quantification Fig. 6b, and additional pictures in Supplementary Fig. 11).

It has been reported that PLIN5 localizes to mitochondria in muscle58 and that PLIN5 recruits mitochondria to the LD surface31. The Shirihai group has reported that, during cold exposure of mice, LD–mitochondria contact sites in BAT are decreased when compared to thermoneutrality, and that mitochondria that are not in contact with ("cytoplasmic mitochondria") have increased capacity for fatty acid oxidation relative to LDs that form contact sites with mitochondria ("peridroplet mitochondria")59. Given these provocative findings, we quantified the number of mitochondria in contact with LDs (LD), as well mitochondria–LD contact area normalized by LD perimeter and mitochondrial perimeter (Supplementary Fig. 12a) in the BAT of BATiPLIN5 and Control mice. We observed a decrease in LD–mitochondria contact in mice exposed to 6 °C compared with 23 °C in both Control and BATiPLIN5 mice. Interestingly, we also observed a decrease in LD–mitochondria contact number and area in the BATiPLIN5 compared to Control mice, but only when housed at 23 °C. In the context of the Shirihai finding that cytoplasmic mitochondria in BAT are more oxidative than peridroplet mitochondria, our data suggest that more mitochondria in the BAT of BATiPLIN5 mice have an oxidative phenotype than in Control mice. We also measured mitochondrial area and length (aspect ratio as major axis divided by the minor axis; Supplementary Fig. 12b). We found that in the Control mice mitochondrial area was smaller when the mice were exposed to 6 °C than when maintained at 23 °C, and that mitochondrial area in BATiPLIN5 mice at 23 °C was similar to mitochondrial area of Control mice at 6 °C.

Given the remarkable changes in mitochondrial morphology at 23 °C in the BAT of BATiPLIN5 mice compared with Control mice, we assessed mitochondrial function by two additional methods from samples obtained from mice of these genotypes housed at 23 °C. First, citrate synthase activity measured in BAT lysates was higher in BATiPLIN5 mice (Supplementary Fig. 13a). Second, we measured OCR in isolated mitochondria from mice housed at 23 °C. We decided to measure OCR in isolated mitochondria (same mass of mitochondria as determined by total protein for both genotypes) rather than intact cells, in order to eliminate the possible confounding factor of increased mitochondrial biogenesis in the BATiPLIN5 mice. Substrate-driven mitochondrial respiration in BATiPLIN5 mice was greater than in Control mice (Fig. 6c). We used guanosine diphosphate (GDP), an inhibitor of UCP1, to query the contribution of UCP1-driven respiration. Interestingly, in response to GDP the OCR of mitochondria from BATiPLIN5 mice fell to levels even lower than that of Control mice (Supplementary Fig. 13b). These data suggest that the OCR increase in the BATiPLIN5 mice is dependent on UCP1 function, or at least on intact mitochondrial function.

To further study whether UCP1 function is necessary for the phenotype in the BATiPLIN5 mice, we generated a mouse model with both inducible PLIN5 overexpression in BAT and constitutive UCP1 deficiency in BAT by crossing our BATiPLIN5 mouse with the UCP1 knockout mouse generated by Leslie P. Kozak67 [Jackson Laboratories (B6.129-UCP1tm1Kfl/J Stock No: 003124)]. First, we validated the mouse models by assaying PLIN5 and UCP1 protein expression in BAT and found a 6–7-fold increase in PLIN5 protein expression in the BATiPLIN5 and UCP1KO/BATiPLIN5 mice, and no UCP1 expression in the UCP1KO and UCP1KO–BATiPLIN5 mice (Supplementary Fig. 14a). Next, we tested glucose tolerance by OGTT and found an improvement in glucose tolerance in the BATiPLIN5 mice compared with Control mice, as we observed before. However, in the UCP1KO–BATiPLIN5 mice, this improvement was not observed (Fig. 6d). In agreement with the results reported above, BATiPLIN5 mice showed smaller inguinal white adipocytes compared with Control mice (Supplementary Fig. 15a, bottom left panel); however, this feature was absent in the UCP1KO/BATiPLIN5 mice (Supplementary Fig. 15a, bottom right panel).

**Perilipin 5 associated changes in mitochondrial cristae packing require conserved ATGL and SIRT1 function.** As noted above, previous reports have suggested a role for PLIN5 in lipolysis regulation via interaction with ATGL and ABHD528,29. We and others have demonstrated that PLIN5 promotes PGC1α function by disinhibiting SIRT1 deacetylase activity34,58, and the Mashek group has elegantly shown that one mechanism of that activation is the delivery by PLIN5 of a fatty acid released by lipolysis to SIRT1 (ref. 58). For this reason, we decided to test whether the changes in mitochondria cristae are maintained in BATiPLIN5 mice when either ATGL or SIRT1 are pharmacologically inhibited. We injected an ATGL inhibitor (Atglistatine) or Vehicle or SIRT1 inhibitor (EX-527) or Vehicle intraaperitoneally daily for 7 days in BATiPLIN5 and Control mice. To confirm inhibition of ATGL by Atglistatine in BAT, we measured ex vivo lipolysis in minced BAT explants. We observed a statistically significant decrease of glycerol release from explants of both the BATiPLIN5 and Control mice with Atglistatine (Supplementary Fig. 16a). To test the inhibitory effect of EX-527 on SIRT1 deacetylase activity, we measured this activity in BAT nuclear extracts. We observed a
statistically significant reduction of SIRT1 activity in nuclear extracts from both Control and BATiPLIN5 mice with EX-527 treatment (Supplementary Fig. 16b). We also observed a statistically significant increase in SIRT1 activity in BAT nuclear extracts from BATiPLIN5 mice treated with Vehicle relative to Control mice.

After confirming inhibition of ATGL and SIRT1, we performed EM in mice housed at 23 °C. As before, we observed an increase in mitochondria cristae packing and smaller mitochondria in the BATiPLIN5 compared with Control mice, but this increase was attenuated when we inhibited either ATGL or SIRT1 (Fig. 6e).

Quantification of cristae length showed a statistically significant increase in the BATiPLIN5 mice treated with Vehicle that was reduced in the BATiPLIN5 mice treated with Atglistatine or EX-527 (Fig. 6f, top panel), and mitochondrial area was increased in BATiPLIN5 mice treated with Atglistatine or EX-527 (Fig. 6f, bottom panel). Additional electron micrographs at lower magnification from this experiment are shown in Supplementary Fig. 17.

**Plin5 gene knockout in BAT impairs BAT mitochondrial respiration but leads to iWAT compensation.** To address whether expression of PLIN5 in BAT is required for maintenance of mitochondrial function in BAT and of systemic glucose homeostasis, we generated mice with constitutive PLIN5 deficiency, specifically in BAT. First, we introduced LoxP sites flanking exons 3 through 8 of the *Plin5* gene by homologous recombination (see Methods).
recombination in C57BL/6 embryonic stem (ES) cells to create the Plin5lox/lox strain. This strategy was chosen to minimize possible creation of an in-frame hypomorphic allele upon Cre-mediated recombination. We then crossed the Plin5lox/lox mice with UC1P-Cre mice generated by Evan D. Rosen [Jackson Laboratories, B6.FVB-Tg(UCP1-Cre)1Evdr/J Stock No: 024670], as outlined in Fig. 7a. We named this model BKOP5IN5. To validate our model, we performed western blot (WB) for PLIN5 in the indicated tissues and found PLIN5 deletion only in BAT (Fig. 7b), and we confirmed these results by qPCR (Fig. 7c). We used qPCR for PLIN5 in iWAT due to the very low levels of PLIN5 protein in wild-type mice. We found no deletion of PLIN5 in the iWAT of BKOP5IN5 mice housed at 23 °C or exposed to 6 °C overnight (Fig. 7j). We next investigated histological changes in the BAT of BKOP5IN5 mice and found a marked reduction of LDs in the BKOP5IN5 mice housed at 23 °C, exposed to 30 °C for 7 days or housed at 6 °C overnight (Fig. 7d and Supplementary Fig. 18a). We also tested BAT expression of two key thermogenic genes, Ucp1 and Ppargc1a, and found a significant reduction in BKOP5IN5 mice relative to Control mice housed at 23 °C or exposed at 6 °C overnight (Fig. 7c). We performed electron microscopy of BAT to investigate mitochondrial morphology in the BKOP5IN5 mice at both 23 °C and overnight 6 °C. We found no marked differences in mice housed at 23 °C between Control and BKOP5IN5 mice. However, at 6 °C, while Control mice showed an increase in mitochondrial cristae

Fig. 7 BAT-specific knockout of Plin5 impairs BAT mitochondrial morphology and respiration but leads to iWAT compensation (data for Control mice are in black and for BKOP5IN5 mice in orange). a Schematic representation of Plin5 gene knockout in BAT (BKOP5IN5 mice). b WB for PLIN5 expression from the indicated tissues of Control or BKOP5IN5 mice housed at 23 °C or exposed to 6 °C for 16 h. c Relative mRNA expression by qPCR for the indicated genes in BAT from Control or BKOP5IN5 mice housed at 23 °C or exposed to 6 °C for 16 h. n = 4 mice per group. d Representative image of hematoxylin and eosin staining of BAT from Control or BKOP5IN5 mice housed at 23 °C, housed for 7 days at 30 °C or exposed to 6 °C for 16 h. Scale bar = 100 μm. e Right panel: quantification of total mitochondria cristae length normalized to mitochondrial area in BAT from Control or BKOP5IN5 mice housed at 23 °C or exposed to 6 °C for 16 h. n = 50 mitochondria/group. f Oxygen consumption rate (OCR) from BAT mitochondria isolated from Control or BKOP5IN5 mice housed at 23 °C after sequential injection of pyruvate/malate and GDP. n = 3 per group. g OGTT after 8 weeks on chow diet (left panel) or HF diet (right panel). Chow diet Control n = 10, BKOP5IN5 n = 11. h Weight of Control (n = 10 per group) or BKOP5IN5 (n = 11 per group) mice fed Chow or HF diet for 12 weeks. i Acute cold tolerance test performed on Control (n = 5 mice) or BKOP5IN5 (n = 7 mice). j Relative mRNA expression by qPCR for the indicated genes in iWAT from Control or BKOP5IN5 mice housed at 23 °C or exposed 6 °C for 16 h. n = 4 mice per group. Values are mean ± s.e.m. For c, e, and j, statistical analysis was performed using two-way ANOVA followed by Tukey posttest. P values are shown in the figure. For f and g, statistical analysis was performed using unpaired two-sided Student’s t test. For g and h, p values are shown in the figure. For i, p values as follow: *time 28 p = 0.0016, *time 34 p = 0.0021, *time 41 p = 0.0044, *time 47 p = 0.0141, *time 54 p = 0.0473. Source data are provided as a Source data file.
packing compared with 23 °C, BKOPLIN5 mice instead had a
decrease in cristae packing and altered mitochondrial cristae
morphology at 6 °C (Fig. 7e, left panel and Supplementary
Fig. 19a). As a quantititative measure of cristae packing, we
assessed total cristae length normalized to mitochondrial area.
By this measure, Control mice had increased total cristae packing
when housed at 6 °C compared with 23 °C, but BKOPLIN5 mice
had a marked decrease at 6 °C compared with 23 °C (Fig. 7e, right
panel). We found no difference between Control and BKOPLIN5
mice in LD–mitochondria contacts (Supplementary Fig. 19b).
Mitochondrial area was increased and mitochondrial length
decreased in the BKOPLIN5 mice during cold exposure in
BKOPLIN5 compared with Control mice (Supplementary
Fig. 20a).

To test mitochondrial function in the BKOPLIN5 mice, we
measured OCR in isolated mitochondria obtained from mice
housed at 23 °C. We observed a significant reduction in OCR in
BKOPLIN5 mice compared with Control mice (Fig. 7f). We next
investigated the systemic effects of BAT PLIN5 deficiency. We
found a small decrease in glucose tolerance at the 60 min
timepoint in BKOPLIN5 mice on chow and no difference in
glucose tolerance on HFD (Fig. 7g). There were no differences in
more so at 6 °C. In line with our previous report that nuclear
magnetic resonance at 23 °C. This finding suggests the
possibility that increased PLIN5 expression in BAT leads to the
increased recruitment of new adipocytes in iWAT, an adipose
depot that is resistant to adipocyte hyperplasia and generally
possesses greater systemic insulin sensitivity67. The smaller size of white
adipocytes in BATiPLIN5 mice suggests a healthy remodeling of the iWAT depot, which is
supported by our finding of decreased markers of inflammatory
gene expression, increased insulin signaling as assessed by
phospho-AKT/total AKT, and increased Glut4 mRNA. In other
mouse models, Glut4 gene expression in iWAT correlates posi-
tively with systemic insulin sensitivity57. The smaller size of white
adipocytes in the iWAT of BATiPLIN5 mice was not associated
with any changes in whole body fat mass, as determined by
nuclear magnetic resonance at 23 °C. This finding suggests the
possibility that increased PLIN5 expression in BAT leads to the
increased recruitment of new adipocytes in iWAT, an adipose
depot that is resistant to adipocyte hyperplasia and generally
expands by hypertrophy, especially in male mice68. It is important
to note that, in the iWAT of BATiPLIN5 mice, gene expression
for PLIN5 and other thermogenic genes is downregulated, espe-
cially during acute cold exposure, and there is a trend toward

Discussion
In this study, we provide the first report that in wild-type mice
PLIN5 mRNA and protein expression levels markedly increase in
BAT during exposure to cold. Based on the data from genetically
engineered mouse strains, we demonstrate herein that PLIN5 in
BAT plays a critical role in the adaptive response of BAT to cold
stress with respect to fatty acid uptake and oxidation, increased
cristae packing in mitochondria, and UCP1-dependent mito-
chondrial respiration. Further, we show that PLIN5 function in
BAT influences systemic glucose metabolism via secondary effects
on iWAT (adipocyte size, thermogenic gene expression, inflam-
matory gene expression, insulin signaling, and lipolysis) and liver
(steatosis, insulin signalling).

In our hands, driving increased expression of PLIN5 in brown
adipocytes using the Tet-On system in mice housed at 23 °C
mimicked the effect of overnight exposure to 6 °C, with respect to
cristae packing in mitochondria. Because mitochondrial cristae
are the subcompartment of the mitochondrial inner membrane
that harbors the machinery of oxidative phosphorylation59, it is
not surprising that isolated mitochondria from BATiPLIN5 mice
have augmented substrate-driven respiration. Augmentation of
mitochondrial cristae, a trend toward increased mitochondrial DNA,
increased citrate synthase activity, and increased respira-
tion were consistent with the PLIN5-dependent changes in BAT
thermogenic gene expression that we observed at 23 °C, and even
more so at 6 °C. In line with our previous report that nuclear
PLIN5 activates SIRT1 activity34, we observed an increase in

SIRT1 activity in BATiPLIN5 mice. We also demonstrated that
SIRT1 inhibition attenuates the increase in mitochondrial cristae
packing that we have described in the BATiPLIN5 mice. The
effects of PLIN5 on gene expression in BAT were consistent with
our previous published report that during catecholamine-
stimulated lipolysis nuclear PLIN5 promotes transcription of
genes involved in mitochondrial biogenesis and function via
interaction with SIRT1–PGC1α complexes34.

In keeping with the augmentation of both thermogenic gene
expression and of mitochondrial function in BAT, BATiPLIN5
mice were more tolerant to acute cold challenge by 8 h of fasting
than Control mice, and they maintained a higher core body
temperature throughout 3 weeks of cold acclimation when fed ab
libitum. Two elegant studies in genetically engineered mouse
models have demonstrated that adaptive non-shivering thermo-
genesis in BAT requires fatty acids derived from triglyceride
lipolysis in WAT during fasting or from circulating triglycero-
rich lipoproteins in the fed state to serve as substrates for
uncoupled mitochondrial respiration and to activate UCP1
(refs. 60,61). Surprisingly, lipolysis in brown adipocytes is not
required for adaptive thermogenesis in BAT59,61. In BATiPLIN5
mice, neither basal nor β-3 agonist-stimulated lipolysis was
augmented compared with Control mice, as assessed by mea-
surement of glycerol efflux from minced BAT tissues. In other
experimental contexts, PLIN5 has been shown to have a role in
limiting basal lipolysis and augmenting catecholamine-stimulated
lipolysis, both in cells28,29 and in mouse models of PLIN5 over-
expression in heart36,62 or knockout in heart63 and liver38. It is
possible that PLIN5 plays a less central role in regulating lipolysis
in BAT due to the high level of Perilipin 1 (PLIN1), which is also
expressed in BAT25 and is proposed to regulate lipolysis in
BAT64. Even though BAT PLIN5 overexpression does not affect
BAT lipolysis, systemic pharmacological inhibition of ATGL
lipase activity attenuates the phenotype of increased cristae
packing in the mitochondria of BATiPLIN5 mice. Additional
studies are necessary to clarify this effect, because it remains
unclear whether it is inhibition of ATGL in other tissues, such as
WAT or heart, or of PLIN1-regulated ATGL activation in BAT
that blocks the phenotype.

In contrast to lipolysis in BAT, β-3 agonist-stimulated lipolysis
in iWAT was increased in BATiPLIN5 mice. Increased basal
and catecholamine-stimulated lipolysis have been associated with
white adipocyte hypertrophy55, but in BATiPLIN5 mice inguinal
white adipocytes were significantly smaller than in Control mice.
Smaller adipocytes may be a marker for greater systemic insulin
sensitivity. For example, in a study of healthy overweight adults,
ahypocaloric diet resulted in weight loss and improvement in
insulin sensitivity, and the best predictors of improvement were
decreased adipocyte size and reduced waist circumference66. The
reduction in inguinal white adipocyte size in BATiPLIN5 mice
suggests a healthy remodeling of the iWAT depot, which is
supported by our finding of decreased markers of inflammatory
gene expression, increased insulin signaling as assessed by
phospho-AKT/total AKT, and increased Glut4 mRNA. In other
mouse models, Glut4 gene expression in iWAT correlates posi-
tively with systemic insulin sensitivity57. The smaller size of white
adipocytes in the iWAT of BATiPLIN5 mice was not associated
with any changes in whole body fat mass, as determined by
nuclear magnetic resonance at 23 °C. This finding suggests the
possibility that increased PLIN5 expression in BAT leads to the
increased recruitment of new adipocytes in iWAT, an adipose
depot that is resistant to adipocyte hyperplasia and generally
expands by hypertrophy, especially in male mice68. It is important
to note that, in the iWAT of BATiPLIN5 mice, gene expression
for PLIN5 and other thermogenic genes is downregulated, espe-
cially during acute cold exposure, and there is a trend toward

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23601-2
ARTICLE
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23601-2
11
decreased expression of these genes at normal housing temperatures. This finding may point to the existence of compensatory negative feedback from BAT to iWAT, such that increased thermogenic activity in BAT leads to the reduced thermogenic activity in iWAT. In any event, the reduction in iWAT cell size and increase in iWAT insulin sensitivity are not explained by iWAT being, as indicated by the reduced expression of Ucp1 in that depot and the unchanged expression of markers of sympathetic innervation. It will be important to determine whether brown adipocytes in BATiPLIN5 mice secrete a factor or factors that stimulate WAT hyperplasia, as well as promote WAT lipolysis to fuel BAT uncoupled respiration.

In addition to fatty acids derived from lipolysis in BAT, fatty acid substrates to fuel thermogenesis in BAT may be derived from glucose uptake and de novo lipogenesis in BAT, or from the hydrolysis of triglycerides in circulating triglyceride-rich lipoproteins. In BATiPLIN5 mice, we found that increased lipolysis in iWAT was accompanied by the increased uptake and oxidation of fatty acids in BAT. When housed at 23 °C, BATiPLIN5 mice did not exhibit differential expression in BAT of genes involved in the uptake of fatty acids into brown adipocytes (Cd36, Fatp1) or in the release of fatty acids from triglyceride-rich lipoproteins (Lpl, Angplt4); however, short-term exposure of these mice to 6°C was associated with a significantly greater rise in Lpl RNA in BATiPLIN5 compared with Control mice. We did not observe an increase in BAT glucose uptake in the BATiPLIN5 mice, and DNL gene expression after short cold exposure was similar between Control and BATiPLIN5 mice. Interestingly, housing mice under the mild cold stimulus of 23 °C revealed an increase in DNL gene expression in BATiPLIN5 mice compared with Control mice. In a recent study, mice exposed to mild cold (22 °C) for 28 days showed an induction of DNL genes, when compared with mice housed at thermoneutrality. These collective data may delineate a dual role for PLIN5 during cold adaptation, whereby PLIN5 is involved in promoting de novo lipogenesis during chronic mild chronic cold exposure, and LPL-mediated fatty acid uptake during more severe acute cold exposure.

The healthy remodeling of iWAT in BATiPLIN5 mice was accompanied by reduced hepatic TAG content on chow and resistance to hepatic steatosis on a HFD, which we documented by histology and measurement of hepatic triglycerides. BATiPLIN5 mice also exhibited reduced blood glucose excursions during pyruvate tolerance testing, which is consistent with a reduction in hepatic gluconeogenesis. The reduction in both hepatic steatosis and hepatic gluconeogenesis would follow from improved iWAT insulin sensitivity and hepatic insulin sensitivity, respectively, which we demonstrated by the assessment of insulin-stimulated AKT phosphorylation in those tissues. Collectively, our data strongly support an increase in both hepatic and iWAT insulin sensitivity. Ultimately, in BATiPLIN5 mice, the improved insulin sensitivity in liver and iWAT was associated with improved glucose tolerance achieved at lower circulating insulin levels, which suggests improvement in systemic insulin sensitivity.

Notably, the effects of PLIN5 overexpression in BAT on systemic glucose tolerance were negated when BATiPLIN5 mice were bred onto a Ucp1 knockout background, and the decrease in iWAT adipocyte size was also lost. Also, during mitochondrial respiration experiments, the mitochondrial OCR of BATiPLIN5 mice showed a greater inhibition to GDP (a Ucp1 inhibitor) than that of Control mice. A study previously reported that UCP1 knockout on the C57BL/6 background strain is associated with reduced electron transport chain proteins in mitochondria, as well as dysmorphic mitochondria during chronic cold acclimation. Thus, the positive metabolic effects of increased PLIN5 expression in BAT are dependent on UCP1 expression and/or intact mitochondrial respiratory function. Remarkably, PLIN5 BAT overexpression has a profound effect on increasing mitochondrial cristae packaging even at 23 °C, and the BKOPLIN5 mice showed loss of mitochondrial cristae during cold exposure.

PLIN5 knockout specifically in BAT (BKOPLIN5) was not associated with marked worsening of glucose tolerance, as might have been predicted by the improvement of glucose tolerance observed with PLIN5 overexpression in BAT, though there was a small statistically significant worsening at the 60-min timepoint in the OGTT. Nor was cold tolerance reduced in BKOPLIN5 mice, as might have been expected given the improved cold tolerance we observed in BATiPLIN5 mice. These data raise the question of whether the glucose and cold tolerance phenotypes of the BATiPLIN5 mice reflect the normal function of PLIN5 in BAT or rather represent neomorphic phenotypes. We consider the possibility of neomorphic phenotypes unlikely, because the BAT of BKOPLIN5 mice has significantly reduced expression of key thermogenic genes, has reduced substrate-driven respiration, and exhibits reduced mitochondrial cristae packaging during cold stress compared with Control mice. The mostly preserved glucose tolerance and cold tolerance in BKOPLIN5 mice are likely due to compensation that occurs in iWAT in the setting of chronic PLIN5 deficiency in BAT, as suggested by a trend toward increased Ucp1 at 23 °C and Ppargc1a and Ucp1 at 6 °C in the BKOPLIN5 iWAT compared to Control mice. Also, Ppargc1a and Ucp1 gene expression in iWAT showed a more robust and statistically significant response to overnight cold exposure in the BKOPLIN5 mice, when compared to Control mice.

The idea that human brown or beige adipose tissue is a promising target for the development of therapeutics to address type 2 diabetes is reinforced by our finding that increasing PLIN5 in mouse BAT promotes glucose tolerance, healthy remodeling of iWAT, and protection against hepatic steatosis on a HFD. We have shown that more PLIN5 in brown adipocytes augments mitochondrial oxidative function, and promotes the uptake and oxidation of fatty acids in BAT. This model (Fig. 8) is consistent with the conception of BAT as a “metabolic sink” that utilizes fatty acids mobilized from WAT as fuel for uncoupled mitochondrial respiration. Further, with the additional stimulus of cold exposure, BATiPLIN5 mice lose more weight than Control mice despite eating more food. This finding suggests the possibility that pharmacologic augmentation of PLIN5 expression coupled with an additional stimulus might work synergistically to promote lose of adipose mass as a means to treat obesity. How to effectively, safely, and specifically promote PLIN5 expression in the thermogenic adipose tissue of mice and humans is not currently known. Our studies reported here suggest the potential of PLIN5 to mimic the effect of cold temperature on BAT and, thereby, to improve systemic glucose tolerance and protect against diet-induced hepatic steatosis.

Our current work has several limitations. We have not yet discovered the mechanistic link between augmented PLIN5 function in BAT and the promotion of smaller, more insulin sensitive white adipocytes in WAT, though we have shown that the mechanism is not increased beiging of iWAT nor increased secretion of FGf21 by BAT. Also, we have not shown directly that the smaller iWAT adipocytes are due to hyperplasia, which would be unusual in that depot, at least in male mice. Finally, though we think it likely that the effects of PLIN5 on mitochondrial structure and function in BAT are mediated in large part by promotion of the increased activity of the SIRT1/PGC1α transcriptional program, we have not ruled out a role for PLIN5 via its direct physical association with mitochondria. These questions remain for further study.
Methods

Animal studies. We performed all animal experiments with approval from the University of Texas Southwestern Medical Center (UTSW) Institutional Animal Care and Use Committee, and all experiments were performed in adherence to the guidelines of National Research Council, 2011, Guide for the Care and Use of Laboratory Animals: Eighth Edition.

The UTSW Transgenic Core assisted in generation of the TRE-Plin5 and Plin5<i>loxp/loxp</i> genetic mouse models on a C57BL/6J background. For all experiments presented in this study, we used male mice on a C57BL/6J background. We housed mice in a conventional animal facility at 23 °C in a 12-h light/dark cycle with free access to food and water, unless otherwise indicated in the text, figure legends, or “Methods”. For controlled temperature experiments, we housed mice in a thermoneutrality box at 30 °C (Powers Scientific Inc., Model # R1705D) or cold box (Powers Scientific Inc., Model # R1705D) at 6 °C. Mouse euthanasia was by isoflurane anesthesia followed by cervical dislocation. We performed all animal experiments with approval from the University of Texas Southwestern Medical Center (UTSW) Institutional Animal Care and Use Committee, and all experiments were performed in adherence to the guidelines of National Research Council, 2011, Guide for the Care and Use of Laboratory Animals: Eighth Edition.

Diets and timeline for experiments. For BATiPLIN5 and UCP1KO/BATiPLIN5 mice, we used special diets that contained 200 mg of DOX/kg diet and were referred to as Chow (Bioserve, S3888) or HFD (60% high fat, Research Diets, D09050201). Unless otherwise indicated, we started the special diet 8 weeks after birth, and in general experiments were performed 12–16 weeks after birth (4–8 weeks after initiation of special diet). For all experiments involving the DOX-inducible transgene (TRE-Plin5), DOX-containing diets were fed to both Control and experimental groups. For the BKOPLIN5 mice, we used chow diet (Teklad, 2016). Except for experiments involving the DOX-inducible transgene, UCP1rtTA strain and control strain UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−, Experimental strain 1 (UCP1KO) UCP1KO-UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−, Experimental strain 2 (BATiPLIN5) UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−, Experimental strain 3 (UCP1KO/BATiPLIN5) UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−. For BKOPLIN5: Control strain Plin5/+; Ucp1-Cre/+; TRE-Plin5/−/−; UCP1RTTA/−/−/−/−; UCP1KO/−/−, Experimental strain 1 (UCP1KO) UCP1KO-UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−, Experimental strain 2 (BATiPLIN5) UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−, Experimental strain 3 (UCP1KO/BATiPLIN5) UCP1rtTA/−/−; TRE-Plin5/−/−; UCP1KO/−/−. For BATiPLIN5 and BKOPLIN5 mice are available upon request from the corresponding author of this manuscript.

Other mouse lines used in this manuscript can be obtained from standard commercial sources specified in these methods.

Fig. 8 Working model for PLIN5 function in BAT and its role in systemic metabolism. Increasing PLIN5 expression in mouse BAT is sufficient to promote increased fatty acid uptake, fatty acid oxidation, and mitochondrial uncoupled respiration in BAT. One mechanism for these changes is the promotion of the thermogenic gene program. The effects of PLIN5 overexpression on BAT mitochondria mimic the effects of cold exposure in terms of increased cristae packing. These changes in BAT are accompanied by improved acute cold tolerance and chronic cold acclimation and by improved systemic glucose tolerance and resistance to hepatic steatosis on high-fat diet. The improved glucose tolerance is accompanied by healthy iWAT remodeling, as reflected by reduced white adipocyte size and increased insulin sensitivity in iWAT. Genetic deletion of PLIN5 in BAT reveals that PLIN5 is required for normal mitochondrial respiratory function in BAT, as well as for maintenance and augmentation of mitochondrial cristae architecture during cold exposure. Preserved cold tolerance and glucose metabolism in the absence of BAT PLIN5 is likely due to compensatory induction of thermogenic pathways in iWAT.
Cold/thermoneutrality experiments. For Fig. 1b, c, we transferred mice from 23 °C to the indicated temperature box (30 or 6 °C), and after 16 h, we harvested BAT for protein and RNA extraction. For Fig. 1e, we transferred mice from 23 °C to the indicated temperature box (30 or 6 °C), and harvested BAT for protein and RNA extraction at the indicated time points. For body temperature measurements, we used an implantable temperature transponder (iPTT300, BioMedic Data Systems Inc, Seaford, DE) inserted subcutaneously in the back of the mice, using the manufacturer’s needle assembly under general anesthesia with isoflurane via precision vaporizer. To allow recovery, we performed temperature experiments 2–3 days after the transponder insertion. For temperature experiments, we single-housed mice and measured temperature with a thermoprobe reader (CohuMed Systems Inc, Seaford DE), as described below. For Fig. 3b experiment, we measured temperature before we transferred the mice from 23 °C to the 6 °C temperature box. At the time of transfer, we removed food and fasted the mice for 8 h. We measured body temperature, as described above, every hour for 8 h. After 8 h, we returned food to the mice and then maintained the mice in the cold box. For the experiment in Fig. 1e, we measured temperature in mice from experiment described above at 9 a.m. on the indicated days, and provided access to food ad libitum. For the experiment in Fig. 3d, we maintained mice from the experiment described above for 21 days in the cold box. At day 22, food was withdrawn, and we measured body temperature of the mice at the indicated time points.

Body weight. We performed all body weight measurements between 9 and 10 a.m. in fed mice.

Food intake. For food intake measurement, we single-housed mice and measured food weight every morning at 9 a.m. for at least 6 days.

Energy expenditure. Food intake, meal patterns, energy expenditure, and locomotor activity were monitored at the UTSW Metabolic Phenotyping Core, using a commercially available ultrasensitive mouse insulin ELISA kit (Crystal Chem Inc, Cat # 90080), and followed the manufacturer’s instructions. For ITT, we administered insulin Humulin R U-100 ( Lilly USA, Cat # HZ213) by intraperitoneal injection (1 unit of insulin/kg body weight). We collected tail blood at the indicated time points and measured glucose using the Bayer glucometer.

OGTT and ITT. For OGTT, we fasted mice for 5 h. We administered 2.5 g of glucose/kg of body weight by oral gavage and collected tail blood at the indicated time points for measurement of glucose and insulin. For glucose measurement, we used a Contour Next EZ glucometer (Bayer HealthCare LLC), and for insulin, we used a commercially available ultrasensitive mouse insulin ELISA kit (Crystal Chem Inc, Cat # 90080), and followed the manufacturer’s instructions. For ITT, we fasted mice for 5 h. We administered insulin Humulin R U-100 ( Lilly USA, Cat # HZ213) by intraperitoneal injection (1 unit of insulin/kg body weight). We collected tail blood at the indicated time points and measured glucose using the Bayer glucometer.

Serum triglycerides and NEFA measurements. For triglycerides and NEFA measurements, we collected blood for serum preparation after overnight fasting (Fig. 4a) or after overnight exposure to different temperatures (Fig. 4e). For triglycerides measurement, we used Infinity™ triglycerides liquid stable reagent (Cat # TR22421, Thermo Scientific). For calibration, we used Multi calibrator lipids (Cat # 464-01601, Wako). For NEFA quantification, we used HR series NEFA-HR (Cat # 999-34691, Wako) with NEFA standard solution (Cat # 276-7691, Wako).

Histology and adipocyte size quantification and Oil red O staining. To obtain mice tissue samples for histology, we performed cardiac perfusion under ketamine anesthesia. After cardiac perfusion with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, we dissected tissues and fixed with 4% paraformaldehyde solution overnight. The UTSW Molecular Pathology Core Facility performed paraffin embedding, sectioning, H&E staining, and Oil red O staining. We acquired bright-field images using a Keyence BX-710 microscope. Keyence BX-X Analyzer software was used for analysis of bright-field images of H&E stained paraffin sections. For iWAT adipocyte size quantification, >200 adipocytes were quantified in each individual animal (n = 3 mice per group).

Pyruvate tolerance test. We overnight fasted mice and then intraperitoneally injected them with 1 g/kg body weight pyruvate (Cat # PS280 Sigma- Aldrich) diluted in PBS, pH 7.3. We collected tail blood immediately before injection and after injection at the time points indicated in the figure, and measured glucose with the Bayer glucometer referenced above.

Citrate synthase activity. We used a citrate synthase activity colorimetric assay kit (Cat # 318-100, BioVision), and followed the manufacturer’s instructions. We homogenized BAT (~10 mg) with 100 µl of the provided citrate synthase assay buffer, we centrifuged the homogenate for 5 min at 10,000 × g in a microfuge, and collected the supernatant. We added 10 µl of each sample into wells of a 96-well plate and adjusted the volume of each sample to 50 µl with assay buffer. For standard curve preparation, we used the standards provided with the kit. We added reaction mix provided with the kit and immediately read absorbance (OD 420 nm) in a kinetic mode at 25 °C for 40 min.

Mitochondria isolation and OCR measurements. We resuspended ~50 mg of minced BAT in 5 ml of isolation buffer containing 70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM EGTA, and 0.5% (w/v) fatty acid-free bovine serum albumin (BSA, pH 7.2) and homogenized the sample with a motorized Dounce homogenizer by 30 strokes at 500 r.p.m. We centrifuged the homogenate at 800 × g for 10 min at 4 °C and collected the supernatant. We centrifuged the supernatant at 8000 × g for 10 min at 4 °C and discarded the supernatant. We washed the resulting pellet twice with isolation buffer. We resuspended final pellet in 200 µl of resuspension buffer containing 70 mM sucrose, 220 mM mannitol, 10 mM KCl, 5 mM MgCl2, 2 mM Glucose, 1 mM EGTA, and 0.2% (w/v) fatty acid-free BSA. We measured protein concentration with Coomassie Bradford protein assay kit (Thermo Scientific, Cat # 23200). We measured OCRs of the isolated mitochondria using a Seahorse XFP Analyzer (Agilent). Specifically, we loaded 10 µg of isolated mitochondria in 80 µl of resuspension buffer in an XFP miniplate and sequentially injected pyruvate (final concentration 10 mM) and malate (final concentration 5 mM) and GDP (final concentration 1 mM) and measured OCR at the time points indicated in the figures.

Mitochondrial DNA quantification. For isolation of total DNA, 25 µg of tissue was homogenized in PBS using a TissueLyser II and stainless-steel beads (Qiagen, 69989). Samples were processed with Qiagen’s QIAamp DNA Mini Kit (51304) per the kit instructions. Mitochondrial DNA was amplified using primers specific for the mitochondrial cytochrome c oxidase subunit 2 (COX2) gene, and normalized to genomic DNA by amplification of the ribosomal protein s18 (rps18) nuclear gene, using quantitative PCR. We used primers listed in primers table below that were previously described.

EX-527 administration and SIRT1 activity assay. For measurement of SIRT1 deacetylase activity, we used SIRT1 activity assay kit (Abcam Cat # ab516065) following the manufacturer’s instructions. We measured SIRT1 activity from nuclear extracts from BAT of BAPiPLIN5 or Control mice treated with SIRT1 inhibitor EX-527 or Vehicle (Millipore Sigma E7034) at 10 µg/kg/day by intraperitoneal injection daily for 7 days along with DXX diet. After the treatment, we dissected BAT and isolate nuclear extracts as described below. For each reaction and following the volumes recommended by the manufactures instructions, we added to microplate wells 25–30 µl ddH2O, 5 µl of SIRT1 assay buffer, 5 µl fluorosubstrate peptide, 5 µl NAD, and 5 µl of developer. To initiate the reactions, we added our test sample with a final protein concentration of 5 µg in 5 µl volume. For the experiment, we included the following controls: blank control (nuclear extraction buffer), positive control (recombiant SIRT1), and no NAD control. After initiation of the reaction, fluorescence intensity was read at 340–430 nm excitation and 440–460 nm emission. After 1-h reaction was stopped with Stop solution and activity was calculated as the differences in fluorescence intensity between test sample and blank control.

Nuclear isolation for SIRT1 activity assay. We performed all the steps of nuclear isolation at 4 °C. We collected –100 mg of BAT and minced the tissue into small pieces. We resuspended the BAT in 2 ml of isolation buffer containing 10 mM Tris-HCl (pH 7.5), 10 mM NaCl, 15 mM MgCl2, 250 mM sucrose, and 0.1 mM EGTA. Tissue was homogenized with a Dounce homogenizer (40–50 strokes) and the homogenate was decanted into a centrifuge tube, maintained on ice for 30 min, vortexed at maximum speed for 15 s, and then centrifuged at 800 × g for 15 min. After centrifugation, the supernatant was removed and the pellet was resuspended in isolation buffer and centrifuged at 500 × g for 15 min, and subsequently washed in isolation buffer one additional time followed by centrifugation at 1000 × g for 15 min. Finally, the pellet was resuspended in 50 µl of extraction buffer containing 50 mM HEPES KOH (pH 7.5), 420 mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA, and 10% glycerol, sonicated for 30 s, and maintained on ice for 30 min. Finally, the sample was centrifuged at 20,000 × g for 10 min, and the supernatant was used for SIRT1 activity assay.
Electron microscopy. For transmission electron microscopy sample collection, we performed cardiac perfusion under ketamine anesthesia with a perfusion buffer (4% paraformaldehyde, 1% glutaraldehyde, and 0.1 M sodium cacodylate, pH 7.4), and we dissected BAT into 1 mm pieces that were then fixed with 2.5% glutaraldehyde and 0.1 M sodium cacodylate, pH 7.4. Further processing of the samples was performed at UTSW Electron Microscopy Core as follows: tissue samples were rinsed in 0.1 M sodium cacodylate buffer and postfixed in 1% osmium tetroxide and 0.8% potassium ferrocyanide in 0.1 M sodium cacodylate buffer three times for 3 h at room temperature. After three rinses in water they were stained en bloc with 4% uranyl acetate in 50% ethanol for 2 h. Next, the samples were dehydrated with increasing concentrations of ethanol, transitioned into propylene oxide, infiltrated with Epon, before embedding the resin, and polymerized in a 60°C oven overnight. Blocks were sectioned with a diamond knife (Diatome) on a Leica Ultracut 7 ultramicrotome (Leica Microsystems) and collected onto copper grids, post stained with 2% aqueous uranyl acetate and lead citrate. Images were acquired on a JEOL 1400 Plus electron microscope and photographed with a BIORSP16 camera.

Electron micrograph image quantification. For quantification of LD-mitochondria contact sites, mitochondria length, and aspect ratio, we used Image J software (NIH) and followed protocol in ref. 25. We quantified mitochondria in contact with LDs by count and contact area as % of mitochondrial perimeter or % of LD perimeter (n = 10 EM per group for LD–mitochondria contact) and for mitochondria length and area (all the mitochondria in five EM fields per group). For cristae quantification, we measured the total length of cristae in each mitochondrion and normalized by mitochondria area (n = 50 mitochondria per group).

Insulin signaling by measurement of AKT and pAKT. Mice were intraperitoneally injected with saline or insulin 1.5 U/kg body weight. Mice were sacrificed and tissues of interest were harvested, weighed and snap-frozen tissue pieces in liquid nitrogen. Samples were stored at −80°C and later homogenized for quantification of tissue triglycerides by the UTSW Metabolic Phenotyping Core as follows: frozen tissue sections (liver −100 mg and BAT −50 mg) were homogenized in 1 ml of Folch’s solution, using a TissueLyser II bead multi-sample tissue homogenizer (Qiagen Germantown, MD). The homogenate was transferred to a borosilicate glass tube. The original homogenization tube was further rinsed with 1 ml of Folch’s solution. The organic extracts were combined, in the borosilicate glass tube, mixed by vortexing and centrifuged in a benchtop centrifuge. The organic extract was transferred to a 5 ml graduated glass flask. The remaining pellet was reextracted and organic extracts were combined. Additional Folch’s solution was added to the graduated flask until a volume of 5 ml was reached. Triglyceride levels were determined using a commercial colorimetric enzymatic kit and normalized by tissue weight (Infinity™, Thermo Fisher, Waltham, MA.).

Ex vivo lipolysis assay, glycerol measurement, and Atligstatine administration. We measured ex vivo lipolysis in BAT and iWAT tissues explants as described before26, with minor modifications. We collected BAT and iWAT explants (~20 mg) from fed Control or BATiPLIN5 mice. We minced the fat explants, suspended them in incubation media (DMEM supplemented with 2% fatty acid-free BSA), and transferred the minced explants into wells of a 96-well plate. For basal lipolysis, minced explants were preincubated for 60 min in 150 µl of fresh incubation media, after which we measured glycerol in the incubation media. For stimulated lipolysis, we preincubated minced explants for 60 min in 150 µl incubation media supplemented with 10 µm of CL-316,243 (Sigma-Aldrich C9796) or saline. After preincubation, explants were transferred to fresh incubation media with 10 µM of Triacsin C (Cayman Chemical Cat #10007448) in the incubation media. After media collection, we extracted lipids from the remaining pellet was reextracted and organic extracts were combined. Additional Folch’s solution was added to the graduated flask until a volume of 5 ml was reached. After injection indicated in Fig.4g, and added the blood samples to glass scintillation vials containing 5 ml of scintillation cocktail for measurement. The bottom chloroform phase containing the incorporated lipids was transferred to an empty scintillation vial and evaporated overnight. After evaporation, we added 5 ml of scintillation cocktail, mixed well, and measured radioactivity with a scintillation counter (Beckman Coulter, LS6000).

Tissue glucose uptake. For glucose uptake we performed a modified protocol from ref. 25. We administered by oral gavage 1 mg/g body weight glucose with 20 µCi deoxy-D-glucose, 2-[1-14C]-per mouse as tracer (Perkin Elmer, Cat # NEC495A00). After 1-h, mice were sacrificed and tissues of interest were harvested, weighed, and a small piece was cut, weighed, and solubilized using solvable™ (0.1 ml per 10 mg of tissue) and 200 µl were added to 5 ml of scintillation cocktail in a glass scintillation vial. Radioactivity was measured using a scintillation counter (Beckman Coulter, LS6000).

Triglyceride clearance. For triglyceride clearance, we administered 100 µl of olive oil via oral gavage. We obtained blood samples from the tail vein at the indicated time points in the Fig. 4g. We provide all the uncropped WB in Supplementary Figs. 14–19. Antibodies used in this manuscript are shown in Table 1.

Tissue protein lysate preparation and western blot. We homogenized tissue (~50 mg per sample) in RIPA buffer containing 50 mM tris(hydroxymethyl)aminomethane, 140 mM sodium chloride, 0.1% sodium deoxycholate, 0.5 M ethylene glycol-bis(2-aminoethy- l)-ether)-N,N',N'-tetracetic acid, using a TissueLyser II with stainless-steel beads (Qiagen, Germany). After homogenization, we centrifuged the samples at 14,000 × g for 10 min at 4°C to remove cell debris and collected the supernatants. We measured protein concentration using Pierce™ 660 nm Protein assay reagent (Thermo Scientific Cat #23235). We mixed the samples with 2x protein sample loading buffer (62.5 mM Tris-HCL, 2% SDS, 5% glycol, 0.1% Orange G). For protein electrophoresis, we loaded 20 µg of protein per sample into premade gels [Cisrion™ FXG™ 4–20% (Bio-Rad, Cat # 5671094) or AnyKD (Bio-Rad, Cat # 5671124)] and for protein transfer, we used the Criterion Blotter System™ with Hybond® ECL Nitrocellulose membrane (Bio-Rad, Cat # 1620112). We blocked the membranes post-transfer with 5% nonfat dry milk diluted in Tris-buffered saline with 0.1% Tween-20 (TBS-T for 1 h, and then incubated with the indicated primary antibody with 3% BSA diluted in TBS-T (BSAOTTBS-T) for 12–16 h at 6°C. After primary antibody incubation, we washed the membrane three times for 5 min each with TBS-T, and then incubated with the appropriate secondary antibody from LiCor in BSABTS-T for 30 min. After secondary antibody, we washed membrane three times for 5 min each in TBS-T. We visualized the immunoblotted proteins with the Odyssey CLx near-infrared imaging system (Li-Cor). We provide all the uncropped WB in Supplementary Figs. 14–19. Antibodies used in this manuscript are shown in Table 1.

RNA extraction. We homogenized ~50 mg of tissue in 1 ml of QIAzol (Qagen, Cat #79390) using a TissueLyser II and stainless-steel beads (Qagen, 69989). After homogenization, we centrifuged the samples at 14,000 × g for 5 min and then removed floating fat layer from the top by pipetting; then we added 200 µl chloroform and centrifuged the samples at 14,000 for 15 min. We collected the supernatant and used an RNA extraction kit (Cat #74104, Qagen) to obtain RNA. During RNA purification we used the RNase-Free DNase Set (Cat #79254, Qagen) for DNA digestion.

qPCR. We prepared cDNA with iscript kit, (Bio-Rad Cat # 1708891) using 1 µg of RNA and followed the manufacturer’s instructions, using the following cycles and temperatures: 5 min at 25°C, 30 min at 42°C, 5 min at 85°C and hold at 4°C. After the cDNA preparation, we performed qPCR using Power Sybr green (0.1 µM final concentration for primers) on Applied Biosytem’s Viia7 machine. For qPCR, values are expressed as the mean ± s.e.m. n = 3–5 mice/group. Data are representative of at least two independent experiments. Statistical analysis was
Table 1 Antibodies used for WB.

| Antibody                | Source               | Identifier | Figure used                      | Dilution/use | Raised in |
|-------------------------|----------------------|------------|----------------------------------|--------------|-----------|
| Primaries               |                      |            |                                  |              |           |
| Perilipin               | Progen               | GP31       | 1e, h, 7b and Supplementary 1a, 2a, 14a | 1:1000/WB    | Guinea pig|
| Perilipin (C-terminal)  | Bickel lab           | NA         | 1c                               | 1μg/ml/WB    | Rabbit    |
| Ucp1                    | Abcam                | 209483     | 1c and Supplementary 1a           | 1:1000/WB    | Rabbit    |
| Actin                   | Santa Cruz Biotechnology | sc-47777c | 1c                              | 1:1000/WB    | Mouse     |
| GDI (C-terminal)        | Bickel Lab           | NA         | 1e and Supplementary 1a, 2a, 14a | 1μg/ml/WB    | Rabbit    |
| GAPDH                   | Cell signaling       | 2118 S     | 1h                               | 1:1000/WB    | Rabbit    |
| AKT (total)             | Santa Cruz Biotechnology | sc-1619   | 5d, h                           | 1:1000/WB    | Goat      |
| pAKT                    | Cell signaling       | 4060 S     | 5d, h                           | 1:1000/WB    | Rabbit    |
| Secondaries             |                      |            |                                  |              |           |
| Donkey anti-guinea pig 800CW | Li-Cor          | 926-32411  | 1e, h, 7b and Supplementary 1a, 2a, 14a | 1:15,000     |           |
| Goat anti-rabbit 680RD  | Li-Cor               | 926-68071  | 1c, e, h, 5d, h and Supplementary 1a, 2a, 14a | 1:1000/WB    |           |
| Donkey anti-mouse 800CW | Li-Cor               | 925-32212  | 1c                              | 1:1000/WB    |           |
| Donkey anti-goat 800CW  | Li-Cor               | 926-32214  | 5d, h                           | 1:1000/WB    |           |

Table 2 Primer sequences.

| Gene      | Forward                                    | Reverse                                      | Use        |
|-----------|--------------------------------------------|----------------------------------------------|------------|
| Pin5      | GAGGCAGCAACAGGGCCTACT                      | CAAAGAGTGGTCTATGAGGAGATG                     | qPCR       |
| 18S       | GAG CA GAA CAT TGG CCA AG                  | GGC ATC GTT TAG GGT CAG AA                   | qPCR       |
| Ucp1      | CCC TGG CAA AAA CAG AAG GA                 | AGG TGA TTT GCC TCT GAA TGC                 | qPCR       |
| EloV3     | GCC AAA CTG AAG CAT CCT AAT CTT            | CCC AGA ACC ATC TGC AGA ATC                 | qPCR       |
| Pparγ1    | TGC CAT TGA TAA GAC CGA G                  | TTG GGG TCA TTT GGT GAC                     | qPCR       |
| Dio       | AAG AAG CAC CGG AAC AAG GA                | AGC TGA TTT GCC TCT GAA TGC                 | qPCR       |
| Fasn      | GCT CCT GGG GTC AGC AAT AGC               | TCT TAC AAG CGG CCA TCA                     | qPCR       |
| Prdm16    | TCC GCC TGC AGC AGC AAT AGC              | TCT TAC AAG CGG CCA TCA                     | qPCR       |
| Tfam      | GGC GGC AGT ATC AGT CCA GT                | CCA AGA GGT CTA TCT GCC TGT TGT            | qPCR       |
| Sla2A4 (Slu4) | GCT GGT TGG CCT TCT TTT AGA        | CTC AAG AGC TCT GCC ACA ATG A                | qPCR       |
| Fgfl2     | GCT CCT GGA GGA CCG TTA CA               | CAC AGG TCC CCA GGA TGT TG                 | qPCR       |
| Cd36      | GGA GGC ATT CTG ATC CCA GT                | CTC CTG TCT TTT GCC ACG TC                 | qPCR       |
| Lpl       | CCA CCA TGG GGC CCT AAC TTT GA           | AAT CCA GGC AGA GCC CTT TCT                | qPCR       |
| Angpt4    | GTT TGA AGC ATG AGA AGG TG                | CCA AGA GGT CTA TCT GCC TGT TGT            | qPCR       |
| Slc27A1 (Fatp1) | TCC TAA GGC TGA TGG CTG CAT TTG     | GCA CGC ATG CTA TAG GAT AA T                 | qPCR       |
| Il6       | CCA GAG ATA CAA AGA AAT GAT GG            | ACT CCA GAA GAC CAG AGG AAA T               | qPCR       |
| Adgre1 (F4/80) | CTT TGG CTA TGG GCT TCT AGT C       | GCA AAG AGG ACA GAG TTT ATC GTG            | qPCR       |
| Saa3      | GGA CCT TGG CTG CTA AAG TCA              | ACC CAG TAG TGG CCC CTC TT                  | qPCR       |
| Tfna      | GAG AAA GTC AAG CCG CTA TCT              | GAA GAC TCC TCC CAG GAT TAT G               | qPCR       |
| Cc12 (Mcp1) | AGC ACC AGG CCA CTT TCA CCA             | TCT GGA CCC ATT CCT TCT TGT                 | qPCR       |
| Rsp18     | TGT GTT AGG GGA GTG GTG GAC A            | CAT CAC CCA CTT ACC CCC AAA A               | qPCR (mtDNA) |
| Cox2      | ATA ACC GAG TGG TCG TTC GCA CAA T        | TTT CAG AGG ATC GGC CAT AGA A               | qPCR (mtDNA) |
| Accs2     | GCT TCT CCA TTA TCT TGT                  | CCC GGA CTT ATG CAG GAT T                   | qPCR        |
| Acaca     | GGA GAT GTA CGC TGA CCG AGA A            | ACC CGA GATG TGT TTA T                      | qPCR        |
| Fasn      | GCT GCG GAA ACT TCA GGA AAT              | AGA GAC GTG TCA CTC GAT G                   | qPCR        |
| ChrebpA   | CGA CAC TCA CCC AAC ATC TCT              | TTG TTA CGG AGC ATC TCT                     | qPCR        |
| ChrebpB   | TCT GCA GAG CTG TGT GAG                 | TCT TCT GGA CCC ATC GCC CCC AGG A           | qPCR        |
| Dgat2     | AGT GGC AAT GCT ATC AGT ATC              | TCT TCT GGA CCC ATC GCC CCC AGG A           | qPCR        |
| Th        | GAA GGG CCT CTA TGC TAC CCA             | TGG GGC CTG GAT AGC AGA                     | qPCR        |
| Dhh       | GAC TCA ACT ACG GCC GGC AGT C            | CTG GGT GCA CTT TTC GGT GCA A               | qPCR        |

performed using Student’s t test, if two groups were analyzed or ANOVA followed by Tukey posttest if more than two groups were analyzed. Comparative Ct method (ΔΔCt) was used to analyze all qPCR data. Expression was normalized to that of the 18S ribosomal subunit as endogenous control, and the relative expression was calculated in comparison with reference sample that is indicated in each figure.

Primers. Primers were designed using Primer Express 3.0.1 (Applied Biosystems) or Primer Blast National Center for Biotechnology Information. All primer sequences are in Table 2. Some primer sequences as indicated in the table were used in previously published studies and referenced.

General reagents and chemicals. Tris-glycine-SDS 10× solution, Fisher Bierengars Cat # BP-1341-4; Tris-glycine 10× solution, Fisher Bioreagents Cat # BP-1306-4; Tris-buffered saline, G Biosciences, Cat # R030; Tween-20, Acros Organics Cat # 23336-0010; methanol, Fisher Chemical Cat # A412SK; BSA, Fisher Scientific Cat # BP16001; free fatty acid BSA, Fitzgerald Cat # 30-AB79; HyClone’s Dulbecco’s Modified Eagles Medium, GE Healthcare Life Sciences Cat # SH30022.01; QIAzol Lysis Reagent, Qiagen Cat # 79306; Criterion TM TGX TM 4–20%, Bio-Rad Cat # 57611094; Criterion TM TGX TM Any Kd, Bio-Rad Cat # 5671124; nitrocellulose membrane, Bio-Rad Cat # 1620112; Power Sybr Green, Applied Biosystems Cat # 4367659; Precision Plus Protein Standards, Bio-Rad Cat # 1610377; Dulbecco’s phosphate-buffered saline, Sigma–Aldrich Cat # D8662; Infinity™ triglycerides liquid stable reagent, Thermo Scientific Cat # TR22421; Multi calibrator lipids, Wako Cat # 64-01601; HR series NEFA-HR, Wako Cat # 999-34691; NEFA standard solution, Wako Cat # 276-76491; free glycerol reagent, Sigma–Aldrich Cat # F6428; Glycerol Standard solution, Sigma–Aldrich Cat # G7793; Piec 660 nM Protein Assay Reagent, Thermo Scientific Cat # 22660; 3a70B Complete Counting cocktail, RPI Cat # 111154; Soltvable TM, Perkin Elmer Cat # 6NE9100; paraformaldehyde, Sigma–Aldrich Cat #
P6148; sodium pyruvate, Sigma-Aldrich Cat # P5280; α-(−)-malic acid, Sigma-Aldrich Cat # M1000; GDP sodium salt, Sigma-Aldrich Cat # G7217; α- (+)-glu- cose, Sigma-Aldrich Cat # G7258; β-sucrose, Fisher Bioreagents Cat # BP220-1; o- mannitol, Sigma-Aldrich Cat # M4125; HEPEFS 1 M solution, Sigma-Aldrich Cat # H8087; EGTA, MP Biomedicals Cat # 195174; potassium phosphate monobasic (KH2PO4), Sigma-Aldrich Cat # P5655; magnesium chloride (MgCl2), Sigma-Aldrich Cat # M5528; Tris-base, Fisher Bioreagents Cat # BP152-1; sodium chloride (NaCl), Fisher Scientific Cat # 5675-31; sodium deoxycholate, Sigma-Aldrich Cat # 09370; Tris-HCl 1 M solution, Fisher Bioreagents Cat # BP1757; glycerol, Acros Organics Cat # 337255000; orange G, Sigma-Aldrich Cat # O3756; sodium hydroxide (NaOH), Fisher Scientific Cat # S318-1; sodium dodecyl sulfate (SDS), Invitrogen Cat # 15-525-017; chloroform, Sigma-Aldrich, Cat # C24322; mercapto- toehanol, Fisher Scientific Cat # 034461-106; glacial acetic acid, Fisher Bioreagents Cat # BP2401.

**Statistics and reproducibility.** For statistical analysis, we used GraphPad Prism version 7.00 for MacOS, GraphPad Software, La Jolla California USA, www.graphpad.com.

For all the experiments, data are representative of at least two independent experiments and all attempts to reproduce were successful. P values are indicated in figures or figure legends, and statistical analysis was performed using Student’s t test if two groups were analyzed or ANOVA followed by Tukey posttest if more than two groups were analyzed. Statistical significance is defined as p < 0.05.

**Software.** For WB band intensity analysis, we used Image Studio Ver 3.1 (Lice Biosciences). For qPCR Ct values analysis, we used Quant Studio Real-time qPCR software Ver. 3.1 (Applied Biosystems). Mitochondrial respiration data were analyzed using the Wave Desktop Software Ver. 2.6.1(Agilent technologies). For adipocyte area calculation, we used Keyence BZ-X Analyzer software Ver. 1.3.03. For colorimetric microplate assays (protein quantification, adrenergic receptor agonist), we used Gen5 Ver 2.01.14 software. For quantification of LD-mitochondria contact sites, mitochondria length, and aspect ratio, we used Image J software NIH Ver 1.53.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

The authors declare that all the data supporting the findings of this study are available within the article and its Supplementary Data, or from the corresponding author upon request. Source data are provided with this paper.

Received: 21 January 2020; Accepted: 28 April 2021; Published online: 03 June 2021

**References**

1. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. *Physiol. Rev.* 84, 277–359 (2004).

2. Végipéroloupolou, A. et al. Cytochrome-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. *Science* 328, 1158–1161 (2010).

3. Ishibashi, J. & Seale, P. Beige can be slimming. *Nature Commun.* 32, 1525 (2012).

4. Nicholls, D. G. & Locke, R. M. Thermogenic mechanisms in brown fat. *J. Clin. Investig.* 130, 1917–1927 (2013).

5. Virtanen, K. A. et al. Brief report: functional brown adipose tissue in healthy adult humans effects of cold exposure and adiposity. *Diabetes* 58, 1526–1531 (2009).

6. Peirce, V. & Vidal-Puig, A. Regulation of glucose homeostasis by brown adipose tissue. *Lancet Diabetes Endocrinol.* 1, 353–360 (2013).

7. Townsend, K. L. & Tseng, Y. H. Brown fat fuel utilization and thermogenesis. *Trends Endocrinol. Met.* 25, 168–177 (2014).

8. Sodiosis, L. & Kazimura, S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. *J. Clin. Investig.* 125, 546–559 (2015).

9. Kajimura, S., Spiegelman, B. M. & Seale, P. Brown and beige fat: physiological roles beyond heat generation. *Cell Metab.* 22, 546–559 (2015).

10. Hankir, M. K. & Klingenspor, M. Brown adipocyte glucose metabolism: a heated subject. *EMBO Rep.* 19, e46404 (2018).

11. Yoneshiro, T. et al. Recruited brown adipose tissue as an antiobesity agent in humans. *J. Clin. Investig.* 123, 3404–3408 (2013).

12. Cypess, A. M. et al. Activation of human brown adipose tissue by a beta-3 adrenergic receptor agonist. *Cell Metab.* 21, 33–38 (2015).

13. Blondin, D. P. et al. Selective impairment of glucose but not fatty acid or oxidative metabolism in brown adipose tissue of subjects with type 2 diabetes. *Diabetes* 64, 2388–2397 (2015).

14. Chondronikola, M. et al. Brown adipose tissue activation is linked to distinct systemic effects on lipid metabolism in humans. *Cell Metab.* 23, 1200–1206 (2016).

15. Chondronikola, M. et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. *Diabetes* 63, 4089–4099 (2014).

16. Stanford, K. L. et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. *J. Clin. Investig.* 123, 215–223 (2013).

17. Ouellet, V. et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. *J. Clin. Investig.* 122, 545–552 (2012).

18. Orava, J. et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. *Cell Metab.* 14, 272–279 (2011).

19. Bartelt, A. et al. Brown adipose tissue activity controls triglyceride clearance. *Nat. Med.* 17, 200–203 (2011).

20. Wang, H. et al. Unique regulation of adipose triglyceride lipase (ATGL) by perilipin 5, a lipid droplet-associated protein. *J. Biol. Chem.* 286, 15707–15715 (2011).

21. Graneman, J. G., Moore, H. P., Mottillo, E. P., Zhu, Z. & Zhou, L. Interactions of perilipin-5 (Plin5) with adipocyte triglyceride lipase. *J. Biol. Chem.* 286, 5126–5135 (2011).

22. Busma, M. et al. The lipid droplet coat protein perilipin 5 also localizes to muscle mitochondria. *Histochem. Cell Biol.* 137, 205–216 (2012).

23. Wang, H. et al. Perilipin 5, a lipid droplet-associated protein, provides physical and metabolic linkage to mitochondria. *J. Lipid Res.* 52, 2159–2168 (2011).

24. Mason, R. R. et al. PLIN5 deletion remodels intracellular lipid composition and causes insulin resistance in muscle. *Mol. Metab.* 3, 652–663 (2014).

25. Civelek, M. et al. Genetic regulation of adipose gene expression and cardiovascular traits. *Am. J. Hum. Genet.* 100, 428–443 (2017).

26. Gallardo-Montejano, V. J. et al. Nuclear Perilipin 5 integrates lipid droplet lipolysis with PGC-1alpha/SIRT1-dependent transcriptional regulation of mitochondrial function. *Nat. Commun.* 7, 12723 (2016).

27. Wang, H. et al. Cardiomyocyte-specific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac dysfunction. *J. Lipid Res.* 54, 953–965 (2013).

28. Pollak, N. M. et al. Cardiac-specific overexpression of perilipin 5 provokes severe cardiac steatosis via the formation of a lipolytic barrier. *J. Lipid Res.* 54, 1092–1102 (2013).

29. Trevisi, M. R. et al. Liver perilipin 5 expression worsens hepatosteatosis but not insulin resistance in high fat-fed mice. *Mol. Endocrinol.* 29, 1414–1425 (2015).

30. Wang, C. et al. Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. *Hepatology* 61, 870–882 (2015).

31. Kersten, S. Physiological regulation of lipoprotein lipase. *Biochim. Biophys. Acta 1841*, 919–933 (2014).

32. Mottillo, E. P. et al. Coupling of lipolysis and de novo lipogenesis in brown, beige, and white adipose tissues during chronic beta 3-adrenergic receptor activation. *J. Lipid Res.* 55, 2276–2286 (2014).

33. Sanchez-Gurmaches, J. et al. Brown fat AKT2 is a cold-induced kinase that stimulates ChREBP-mediated de novo lipogenesis to optimize fuel storage and thermogenesis. *Cell Metab.* 27, 195–208 (2018).

34. Irshad, Z., Dimitri, F., Christian, M. & Zimmit, V. A. Diacylglycerol acyltransferase 2 links glucose utilization to fatty acid oxidation in the brown adipocytes. *J. Lipid Res.* 58, 15–30 (2017).

35. Nagle, C. A., Klett, E. L. & Coleman, B. A. Hepatic triacylglycerol accumulation and insulin resistance. *J. Lipid Res.* 50, S74–S79 (2009).
44. Petersen, M. C., Catner, D. F. & Shulman, G. I. Regulation of hepatic glucose metabolism in health and disease. Nat. Rev. Endocrinol. 13, 572–587 (2017).
45. Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91 (2014).
46. Kusminski, C. M., Bickel, P. E. & Scherer, P. E. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15, 639–U684 (2016).
47. Rosen, E. D. & Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847–853 (2006).
48. Czech, M. P. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804–814 (2017).
49. Rutkowski, J. M., Stern, J. H. & Scherer, P. E. The cell biology of fat expansion. J. Cell Biol. 208, 501–512 (2013).
50. Harris, L. A. et al. Perilipin 5-driven lipid droplet accumulation in skeletal muscle stimulates the expression of fibroblast growth factor 21. Diabetes 64, 2757–2768 (2015).
51. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 112, 1796–1808 (2003).
52. Xu, H. Y. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112, 1821–1830 (2003).
53. Han, C. Y. et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in the development of obesity-related insulin resistance. J. Clin. Investig. 112, 1821–1830 (2003).
54. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519–1523 (2011).
55. Cinti, S. The Adipose Organ (Editrici Kurtis, 1999).
56. Benador, I. Y. et al. Mitochondria bound to lipid droplets have unique bioenergetics, composition, and dynamics that support lipid droplet expansion. Cell Metab. 27, 869–885 e866 (2018).
57. Enerback, S. et al. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387, 90–94 (1997).
58. Najt, C. P. et al. Lipid droplet-derived monounsaturated fatty acids via PLIN5 to allosterically activate SIRT1. Mol. Cell 77, 810–824 e818 (2020).
59. Schorr, S. & van der Laan, M. Integrative functions of the mitochondrial contact site and cristae organizing system. Semin. Cell Dev. Biol. 76, 191–200 (2018).
60. Schriever, R. et al. Cold-induced thermogenesis depends on ATG1-mediated lipolysis in cardiac muscle, but not brown adipose tissue. Cell Metab. 26, 753–763 e7e7 (2017).
61. Shin, H. S. et al. Lipolysis in brown adipocytes is not essential for cold-induced thermogenesis in mice. Cell Metab. 26, 764–777 e5 (2017).
62. Pollak, N. M. et al. The interplay of protein kinase A and perilipin 5 regulates cardiac lipolysis. J. Biol. Chem. 290, 1295–1306 (2015).
63. Zheng, P. F. et al. Pim-3 alleviates myocardial ischaemia/reperfusion injury by reducing oxidative stress through inhibiting the lipolysis of lipid droplets. Sci. Rep. 7, 42574 (2017).
64. Souza, S. C. et al. Perilipin regulates the thermogenic actions of norepinephrine in brown adipose tissue. J. Lipid Res. 48, 1273–1279 (2007).
65. Kloting, N. & Bluher, M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev. Endocr. Metab. Disord. 15, 277–287 (2014).
66. McLaughlin, T. et al. Dietary weight loss in insulin-resistant non-obese humans: Metabolic benefits and relationship to adipose cell size. Nutr. Metab. Cardiovasc. Dis. 29, 62–68 (2019).
67. Shepherd, P. R. & Khan, B. B. Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N. Engl. J. Med. 341, 248–257 (1999).
68. Sun, K., Kusminski, C. M. & Scherer, P. E. Adipose tissue remodeling and obesity. J. Clin. Investig. 121, 2094–2101 (2011).
69. Kazak, L. et al. UCP1 deficiency causes brown fat respiratory chain depletion and sensitizes mitochondria to calcium overload-induced dysfunction. Proc. Natl Acad. Sci. USA 114, 7981–7986 (2016).
70. Council, N. R. Guide for the Care and Use of Laboratory Animals: Eighth Edition (The National Academies Press, 2011).
71. Sun, K. et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun. 5, 3485 (2014).
72. Sun, K. et al. Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure. Mol. Metab. 4, 474–483 (2014).
73. Fernandez-Valdivia, R. et al. A mouse model to dissect progresstere signaling in the female reproductive tract and mammary gland. Genesis 48, 106–113 (2010).
74. Kong, X. X. et al. IRF4 is a key thermoergic transcriptional partner of PGC-1 alpha. Cell 158, 69–83 (2014).
75. Price, N. L. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 673–690 (2012).
76. Schweiger, M. et al. Measurement of Lipolysis. Method Enzymol. 538, 171–193 (2014).
77. Mayer, N. et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat. Chem. Biol. 9, 785–787 (2013).
78. Bickel, P. E. et al. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J. Biol. Chem. 272, 13793–13802 (1997).
79. Ye, J. et al. Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13, 134 (2012).

**Acknowledgements**

We dedicate this manuscript to the late Lisa Hahner, who contributed so much her great skill and effort to this project. We thank Philipp Scherer and UT Southwestern Touchstone Diabetes Center for the UCPIrTIA mouse, and his design helping the TRE-Plin 5 transgene. We thank the UT Southwestern Metabolic Phenotyping Core (Ruth Gordillo and Syann Lee), Electron Microscopy Core (Kate Luby-Phelps and Anna Dar-ehshouri), Histology Pathology Core (Bret M. Evers and John M. Shelton), and Transgenic Core (Robert E. Hammer). This study was supported by NIH R01DK115875 for P.E.B., NIH R01DK112826 and R01DK108833 for W.L.H., and Wayne State University Startup funds for R.F.-V.

**Author contributions**

V.I.G.M. conceived the study, carried out experiments, interpreted the data, and wrote the manuscript; C.Y. designed and generated mouse models, and contributed to writing the methods; L.H. assisted with the execution of experiments, genotyped and maintained mice colony, and contributed to writing the methods; J.L.M. assisted with the execution of experiments; R.F.-V. designed the construct for Perilipin 5 KO mouse line; J.A.J. carried out fatty acid uptake and oxidation experiments; W.L.H. assisted with design and interpretation of fatty acid uptake and oxidation experiments; P.E.B conceived and supervised the study, interpreted the data, wrote, and revised the manuscript. All the authors discussed the results and commented on the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-23601-2.

**Correspondence** and requests for materials should be addressed to P.E.B.

**Peer review information** Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021